DDInter605 DDInter1628
Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Drotrecogin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Escitalopram
Escitalopram {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Drotrecogin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Escitalopram
Escitalopram {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Drotrecogin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duloxetine
Duloxetine {u} (Compound) downregulates {v} (Gene) PIN1
PIN1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Drotrecogin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluvoxamine
Fluvoxamine {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Drotrecogin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluoxetine
Fluoxetine {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Drotrecogin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Icosapent
Icosapent {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Drotrecogin alfa {u} may lead to a major life threatening interaction when taken with {v} Tirofiban
Tirofiban {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Drotrecogin alfa {u} may lead to a major life threatening interaction when taken with {v} Meclofenamic acid
Meclofenamic acid {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Drotrecogin alfa {u} may lead to a major life threatening interaction when taken with {v} Ticlopidine
Ticlopidine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Drotrecogin alfa {u} may lead to a major life threatening interaction when taken with {v} Ketorolac
Ketorolac {u} (Compound) downregulates {v} (Gene) DUSP4
DUSP4 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Ruxolitinib (Compound)
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine (Compound) downregulates PIN1 (Gene) and PIN1 (Gene) is downregulated by Ruxolitinib (Compound)
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is bound by Ruxolitinib (Compound)
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Icosapent and Icosapent (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Drotrecogin alfa may lead to a major life threatening interaction when taken with Tirofiban and Tirofiban (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Ruxolitinib (Compound)
Drotrecogin alfa may lead to a major life threatening interaction when taken with Meclofenamic acid and Meclofenamic acid (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Drotrecogin alfa may lead to a major life threatening interaction when taken with Ticlopidine and Ticlopidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Drotrecogin alfa may lead to a major life threatening interaction when taken with Ketorolac and Ketorolac (Compound) downregulates DUSP4 (Gene) and DUSP4 (Gene) is upregulated by Ruxolitinib (Compound)